Burell Scott R 4

What Happened

• Scott R. Burell, a director of Microbot Medical, was reported on Form 4 as receiving an award of 10,000 shares on April 1, 2026. The Form 4 lists the acquisition as an award/grant (transaction code A) at $0.00, so no cash was paid and the reported cash value is $0. The filing classifies the instruments as derivative securities.

Key Details

• Transaction date: 2026-04-01; Form 4 filed: 2026-04-03 (Accession no. 0001493152-26-015151) — filed within the SEC’s two-business-day window (timely).
• Reported transaction: Award/Grant (A) of 10,000 shares at $0.00 (total reported cash paid $0).
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes/plan details: None provided in the supplied data; the filing classifies the grant as a derivative but does not describe vesting, conversion, or other terms.

Context

• Awards and grants are common forms of compensation for directors and often come with vesting or other conditions; they do not necessarily signal the insider’s short-term view of the stock. Because this was recorded as a derivative award, it could be RSUs, restricted shares, or another form of equity compensation — the Form 4 does not specify the exact instrument or vesting schedule.